Preparation of Gelatin Nanoparticles by Two Step Desolvation Method for Application in Photodynamic Therapy.
J Biomater Sci Polym Ed. 2018 Mar 21;:1-24
Authors: Carvalho JA, Abreu AS, Ferreira VTP, Gonçalves EP, Tedesco AC, Pinto JG, Ferreira-Strixino J, Beltrame Junior M, Simioni AR
Gelatin nanoparticles have recently been receiving considerable attention because they offer a good option as release systems due to their low cost, biocompatibility, biodegradability and its application in several types of formulations. This study aim was to evaluate the potential application of gelatin nanoparticles entrapping a photosensitizer in Photodynamic Therapy. Gelatin nanoparticles were studied by steady-state techniques and the biological activity evaluated by in vitro MTT assay. The particles were spherical in shape exhibiting a 273 nm diameter with a low tendency to aggregate. The loading efficiency was 76%. Photosensitizer photophysical properties were shown to be preserved after GN encapsulation. The cells viability obtaining 85% cells death compared with control. The results demonstrate that gelatin nanoparticles can be successfully applied for photosensitizers encapsulation or other active drugs and be used as an optimal medium for a variety of bioactive materials, which can also be encapsulated by the proposed method.
PMID: 29561222 [PubMed - as supplied by publisher]
Biomimetic nanothylakoids for efficient imaging-guided photodynamic therapy for cancer.
Chem Commun (Camb). 2018 Mar 21;:
Authors: Ouyang J, Wang L, Chen W, Zeng K, Han Y, Xu Y, Xu Q, Deng L, Liu YN
Biomimetic nanothylakoids, which are constructed from the thylakoid membrane of vegetable leaves, show high efficiency in tumor microenvironment modulation and photodynamic antitumor therapy under near infrared fluorescence guidance. Furthermore, their outstanding biosafety, facile preparation and low cost make nanothylakoids suitable for further clinical applications.
PMID: 29561035 [PubMed - as supplied by publisher]
Artemisinin and AIEgen Conjugate for Mitochondria-Targeted and Image-Guided Chemo- and Photodynamic Cancer Cell Ablation.
ACS Appl Mater Interfaces. 2018 Mar 21;:
Authors: Feng G, Liu J, Zhang CJ, Liu B
Cell organelle targeting is a promising approach for cancer therapy. Herein, we report a mitochondria-targeted light-up probe (TPETH-Mito-1ART) to co-deliver artemisinin (ART) and an AIE photosensitizer (PS) to mitochondria for image-guided combination cancer cell ablation. This probe contains an AIEgen core of TPETH, two mitochondria targeting arms with ART on one arm, which could be internalized into cancer cells over normal ones, and show predominant accumulation and fluorescence turn-on in mitochondria. The fresh heme produced in mitochondria quickly activates ART, and the direct generation of reactive oxygen species at mitochondria promotes photodynamic therapy (PDT) performance. The combination of ART and PDT leads to largely improved cancer cell ablation efficacy with a synergistic effect, which could quickly depolarize mitochondrial membrane, and largely reduce cancer migration activity. This co-delivery strategy provides great potentials for subcellular organelle-targeted and image-guided combination cancer cell ablation.
PMID: 29560714 [PubMed - as supplied by publisher]
Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids.
Oncotarget. 2018 Feb 27;9(16):13009-13022
Authors: Broekgaarden M, Rizvi I, Bulin AL, Petrovic L, Goldschmidt R, Massodi I, Celli JP, Hasan T
Effective treatment of advanced metastatic disease remains the primary challenge in the management of inoperable pancreatic cancer. Current therapies such as oxaliplatin (OxPt)-based chemotherapy regimens (FOLFIRINOX) provide modest short-term survival improvements, yet with significant toxicity. Photodynamic therapy (PDT), a light-activated cancer therapy, demonstrated clinical promise for pancreatic cancer treatment and enhances conventional chemotherapies with non-overlapping toxicities. This study investigates the capacity of neoadjuvant PDT using a clinically-approved photosensitizer, benzoporphyrin derivative (BPD, verteporfin), to enhance OxPt efficacy in metastatic pancreatic cancer. Treatment effects were evaluated in organotypic three-dimensional (3D) cultures, clinically representative models that bridge the gap between conventional cell cultures and in vivo models. The temporally-spaced, multiparametric analyses demonstrated a superior efficacy for combined PDT+OxPt compared to each monotherapy alone, which was recapitulated on different organotypic pancreatic cancer cultures. The therapeutic benefit of neoadjuvant PDT to OxPt chemotherapy materialized in a time-dependent manner, reducing residual viable tissue and tumor viability in a manner not achievable with OxPt or PDT alone. These findings emphasize the need for intelligent combination therapies and relevant models to evaluate the temporal kinetics of interactions between mechanistically-distinct treatments and highlight the promise of PDT as a neoadjuvant treatment for disseminated pancreatic cancer.
PMID: 29560127 [PubMed]
Scotopic contrast sensitivity and glare after accelerated corneal cross-linking.
Clin Exp Optom. 2018 Jan;101(1):52-56
Authors: Asgari S, Hashemi H, Mohamadi A, Jafarzadehpur E, Miraftab M, Shahhoseini S, Mehravaran S, Fotouhi A
BACKGROUND: The aim was to assess one-year changes in uncorrected and corrected contrast sensitivity (CS) and glare under scotopic conditions after accelerated cross-linking (CXL) using the 18 mW/cm2 protocol for the treatment of progressive keratoconus and compare results with unoperated controls.
METHODS: In this non-randomised clinical trial, 30 eyes were enrolled in the CXL group and 30 were assigned to the control group. Scotopic CS at spatial frequencies (SFs) of 0.5, 1.1, 2.2, 3.4, 7.1 and 15 cycles per degree (cpd) were assessed using the MonCv3System (Metrovision, Pérenchies, France) under scotopic conditions (0.5 lux) at baseline and at six and 12 months.
RESULTS: The mean ages of the participants in the CXL and control groups were 24.32 ± 5.17 and 30.93 ± 7.43 years, respectively (p < 0.001). After adjusting for age, changes in uncorrected and corrected CS and glare were similar in the two groups (all p > 0.05) except for corrected CS at SF 7.1 cpd (1.45 ± 4.31 versus 3.21 ± 4.69 dB, p = 0.010) and 15 cpd (1.12 ± 4.63 versus 3.03 ± 5.48 dB, p = 0.007), which were reduced as an effect of CXL. Based on covariate analyses, among corrected CS indices, corrected CS7.1 and CS15 were related to CXL and their baseline values (all p < 0.050). Uncorrected CS in all SFs and uncorrected and corrected glare were related to their pre-operative values (all p < 0.001).
CONCLUSION: Accelerated CXL can reduce scotopic corrected CS at SFs higher than 7.0 cpd in cases with better baseline values of these parameters. Changes in uncorrected CS and glare are only a factor of baseline values and the indices reduce in cases with better baseline values after one year.
PMID: 28759945 [PubMed - indexed for MEDLINE]